Diligence memo · auto-generated · as of July 3, 2026
HLS Therapeutics Inc.
HLS Therapeutics Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
HLS Therapeutics Inc. operates in Pharmaceuticals, based in CALEDON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
HLS Therapeutics Inc. has raised $143M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $113M on 2015-07-02.
Most recent recorded round closed around 2015-08-11.
Valuation (modeled)modeled
Provath models HLS Therapeutics Inc. at approximately $1.1B (range $143M–$2.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.18× the median modeled value of Series D+ Pharmaceuticals companies in 2013–2015 (6 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 1 months.
Last raise 10.9 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.8× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 95% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: Kv Pharmaceutical Co /De/, Clovis Oncology, Inc., Opko Health, Inc., Horizon Pharma, Inc., Biotie Therapies Corp..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.